Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone
or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in
patients who have not been treated previously or who have relapsed after a previous
successful treatment.
Cryptococcal meningitis is an important cause of disease and death among patients with AIDS.
Usually AMB is given either alone or with FLC to patients with this infection, but these
treatments are not always effective and both have toxic effects. Animal studies and
preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest
that it may be less toxic than either AMB or FLC.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Amphotericin B Fluconazole Flucytosine Liposomal amphotericin B